Search clinical trials for: Anti-CD19 iCAR NK Cells

Total 4132 results

First People's Hospital of Hangzhou
Macera therapeutics

Not yet recruiting

Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases

Gastric Cancer

China
Seoul National University Hospital

Recruiting

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

Very High Risk Acute Lymphoblastic Leukemia | CD19 CAR-T Therapy

Korea, Republic of
Institut Paoli-Calmettes

Completed

Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation (DLI-NK)

Hematological Malignancy

France
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Natural Killer Cells and Bortezomib to Treat Cancer

Multiple Myeloma | Chronic Myeloid Leukemia (CML) | Pancreatic Ca | Colon/Rectal Ca | Carcinoma, Non-Small -Cell Lung

United States
Assistance Publique - Hôpitaux de Paris

Completed

Haploidentical NK-cell Infusion in Acute Myeloid Leukemia (NK)

Acute Myeloid Leukemia

France
Peking University
Peking University Cancer Hospital & Institute

Recruiting

A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

B Cell Non-Hodgkin's Lymphoma

China
Ningbo No. 1 Hospital
Zhejiang University

Recruiting

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Diffuse Large B-cell Lymphoma

China
XuYan

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Chinese PLA General Hospital

Recruiting

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (CART30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Sorrento Therapeutics, Inc.

Withdrawn

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic Antigen

United States
The Catholic University of Korea

Unknown

Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment (ANKL-2)

Non-small Cell Lung Cancer

Korea, Republic of
Charite University, Berlin, Germany
University of Leipzig

Unknown

Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Acute Myeloid Leukemias | Advanced Hematological Malignancies | Indication for Allogeneic Stem Cell Transplantation | no HLA-identical Donor Available

Germany
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Children's Hospital of Philadelphia

Recruiting

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC (ExpMACs)

Leukemia | Bone Marrow Failure Syndromes | Immunodeficiencies | Inborn Errors of Metabolism | Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome

United States
Allife Medical Science and Technology Co., Ltd.
Beijing Hospital; Henan Provincial People's Hospital; The First People's Hospital...

Unknown

A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors

Solid Tumor
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

AML

China
Wuhan Union Hospital, China

Not yet recruiting

CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
OneChain Immunotherapeutics
Hospital Clinic of Barcelona; Hospital Sant Joan de Deu; BioClever 2005 S.L.

Recruiting

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL)

T-cell Acute Lymphoblastic Leukemia | Lymphoblastic T-Cell Lymphoma

Spain
Kai Lin Xu; Jun Nian Zheng
First Affiliated Hospital of Zhejiang University; Nantong University; Affiliated... and other collaborators

Recruiting

Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Takeda

Recruiting

IVIG for Infection Prevention After CAR-T-Cell Therapy

Lymphoma

United States
National Cancer Institute (NCI)

Completed

A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Lymphoma | Leukemia

United States
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.

CD123+ Acute Myeloid Leukemia

China
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Stephan Grupp MD PhD

Recruiting

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Shanghai East Hospital
Nanjing Legend Biotech Co.

Terminated

A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors

Solid Tumors, Adult

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Zhejiang University

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
Seigo Nishida
Florida Department of Health

Completed

Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation (MIAMINK)

Liver Cirrhosis | Hepatocellular Carcinoma | Evidence of Liver Transplantation

United States
Institut Paoli-Calmettes

Completed

Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia (LLC-NK)

Chronic Lymphocytic Leukemia

France
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

United States
920th Hospital of Joint Logistics Support Force...

Recruiting

Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
GI Cell, Inc.

Recruiting

A Study of GIC-102 (Allogeneic Natural Killer Cells) in Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, and Multiple Myeloma

Advanced Solid Tumors | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Non-Hodgkin Lymphoma

Korea, Republic of
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Unknown

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin's Lymphoma

China
University College, London
Deutsche Krebshilfe e.V., Bonn (Germany); European Union; The Leukemia and Lymphoma... and other collaborators

Terminated

CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) (CD19TPALL)

Acute Lymphoblastic Leukemia

United Kingdom, Germany
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Shanghai GeneChem Co., Ltd.
Shanghai Cancer Hospital, China

Unknown

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Carcinoma, Hepatocellular | Colorectal Cancer Metastatic | Pancreatic Cancer Metastatic

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases

Autoimmune Diseases | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Still Disease

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China

Search clinical trials for: Anti-CD19 iCAR NK Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations